$MDT — ADD 📊 | 6 MONTHS THESIS

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and intern 🎯 FQ4 FY2026 | reported Jun 03 | Rev $9.8B | Adj EPS $1.55 vs $1.55 🟢 💡 Consensus appears to underappreciate the breadth of Medtronic's growth acceleration. The Q4 beat was modest at the EPS line (~0.2%) but the revenue outperformance and 'best decade' characterization suggest estimates may be too conservative on the top line. 📉 Reward/risk: 3.1:1 🏢 Business Quality: 7/10 📊 Valuation: At $82.43, MDT trades at ~13.8x the midpoint of FY2027 guided EPS ($5.95). This is below the 15-20x typical for large-cap medtech peers (ABT, BSX,... 🔮 Catalyst: Q1 FY2027 earnings report (expected late August / early September 2026), which will provide the first test of whether 6-7% organic growth is sustainable 💰 Entry: $82.42, stop $79.0, target $93.0 ⚖️ Add MDT at half-size into current levels ($82-83) with a stop a

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and intern